Glucose

Generic Name: Glucose

Brand Names: Bss Ophthalmic Solution, Citrasate, Clinimix 2.75/5, Clinimix E 2.75/5, Dextroject, Dianeal, H.E.L.P.bicel, Hemosate Ultra, Lactate 1-2-3, Leukotrap, Naturalyte, Nauzene, Normosol-R, Nxstage Pureflow, Olimel, Periolimel, Physioneal 40, Sag-M, Sclerodex, Selectbag One

Drug Type: Small Molecule

Unique Ingredient Identifier: IY9XDZ35W2

Background: Glucose is a simple sugar (monosaccharide) generated during phosynthesis involving water, carbon and sunlight in plants. It is produced in humans via hepatic gluconeogenesis and breakdown of polymeric glucose forms (glycogenolysis). It circulates in human circulation as blood glucose and acts as an essential energy source for many organisms through aerobic or anaerobic respiration and fermentation. It is primarily stored as starch in plants and glycogen in animals to be used in various metabolic processes in the cellular level. Its aldohexose stereoisomer, dextrose or D-glucose, is the most commonly occurring isomer of glucose in nature. L-glucose is a synthesized enantiomer that is used as a low-calorie sweetener and laxative. The unspecified form of glucose is commonly supplied as an injection for nutritional supplementation or metabolic disorders where glucose levels are improperly regulated. Glucose is listed on the World Health Organization's List of Essential Medicines.

Indication: Glucose pharmaceutical formulations (oral tablets, injections) are indicated for caloric supply and carbohydrate supplementation in case of nutrient deprivation. It is also used in metabolic disorders such as hypoglycemia.

Associated Conditions: Arrhythmia, Caloric Deficit, Edema of the cerebrum, Hypoglycemia, Metabolic Alkalosis

Associated Therapies: Blood Specimen Collection, Electrolyte replacement, Nutritional supplementation, Parenteral Nutrition, Parenteral rehydration therapy, Plasmapheresis, Positive cardiac inotropic effect, Total parenteral nutrition therapy, Urine alkalinization therapy, Fluid and electrolyte maintenance therapy

Clinical Trials

Efficacy and Safety of Rapid Intermittent Correction Compared With Slow Continuous Correction in Patients With Severe Hypernatremia

Phase 4

Recruiting

Conditions: Hypernatremia

Interventions: Drug: Dextrose 5% in water

First Posted Date: 2021-07-02

Last Posted Date: 2023-08-09

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 144

Registration Number: NCT04949139

Locations: 🇰🇷
Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Gyeonggi-do, Korea, Republic of

Intravenous N-Acetylcysteine for the Treatment of Acute Ischemic Stroke

Phase 2

Conditions: Acute Ischemic Stroke

Interventions: Drug: Dextrose in Water
Drug: Acetylcysteine

First Posted Date: 2021-06-09

Last Posted Date: 2021-06-11

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 118

Registration Number: NCT04918719

Effects of Ultrasound-guide Hypertonic Dextrose Injection for Chronic Subacromial Bursitis

Not Applicable

Conditions: Chronic Shoulder Pain

Interventions: Drug: Triamcinolone Acetonide.
Drug: hypertonic dextrose water

First Posted Date: 2021-06-07

Last Posted Date: 2021-09-05

Lead Sponsor: Taipei Medical University Shuang Ho Hospital

Target Recruit Count: 60

Registration Number: NCT04916353

Locations: 🇨🇳
Shuang Ho Hospital, New taipei city, Zhonghe Dist, Taiwan
🇨🇳
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare, New taipei city, Zhonghe Dist, Taiwan

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

Phase 3

Active, not recruiting

Conditions: Breast Neoplasms

Interventions: Biological: pembrolizumab
Drug: paclitaxel
Drug: nab-paclitaxel
Drug: liposomal doxorubicin
Drug: capecitabine
Drug: normal saline
Drug: dextrose

First Posted Date: 2021-05-20

Last Posted Date: 2025-03-03

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 340

Registration Number: NCT04895358

Locations: 🇺🇸
Parkview Research Center at Parkview Regional Medical Center ( Site 0071), Fort Wayne, Indiana, United States
🇺🇸
University of Illinois at Chicago ( Site 0061), Chicago, Illinois, United States
🇫🇷
Institut de Cancérologie de l'Ouest ( Site 0915), ANGERS cedex 02, Maine-et-Loire, France

and more 253 locations

Dynamic Connectivity Under Metabolic Constraints

Phase 4

Recruiting

Conditions: Insulin Resistance
Healthy
Diet Modification
Aging

Interventions: Drug: Ketones
Drug: Glucose

First Posted Date: 2021-04-09

Last Posted Date: 2023-01-12

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 80

Registration Number: NCT04840095

Locations: 🇺🇸
Martinos Center for Biomedical Research, Building 149, Charlestown, Massachusetts, United States
🇺🇸
Bioengineering Building , Stony Brook University, Stony Brook, New York, United States